memantine has been researched along with Autism Spectrum Disorder in 12 studies
Autism Spectrum Disorder: Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder." | 9.30 | Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies. ( Ali, S; Aman, MG; Andersen, KA; Graham, SM; Hardan, AY; Hendren, RL; Jia, XD; Lateiner, JE; Luchini, R; Mallick, M; Melmed, RD; Palmer, RH; Rahman, R; Robb, A, 2019) |
| "Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders." | 9.22 | Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. ( Abdelgalil, MS; Ali, MM; Benmelouka, AY; Brimo Alsaman, MZ; Elgendy, AMN; Elnaiem, W; Mogheeth, A; Yousof, SM, 2022) |
| "This prospective 12-week open-label trial evaluates the tolerability and efficacy of memantine hydrochloride for the treatment of core social and cognitive deficits in adults with high-functioning autism spectrum disorder (ASD)." | 9.22 | A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder. ( Biederman, J; Chan, J; Conroy, K; Faraone, SV; Fried, R; Furtak, S; Grimsley, E; Joshi, G; Kilcullen, JR; Woodworth, KY; Wozniak, J, 2016) |
| " Dosage of memantine was based on the child's weight and ranged from 3 mg to 15 mg per day." | 6.82 | Memantine for autism spectrum disorder. ( Brignell, A; Marraffa, C; May, T; Williams, K, 2022) |
| "Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder." | 5.30 | Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies. ( Ali, S; Aman, MG; Andersen, KA; Graham, SM; Hardan, AY; Hendren, RL; Jia, XD; Lateiner, JE; Luchini, R; Mallick, M; Melmed, RD; Palmer, RH; Rahman, R; Robb, A, 2019) |
| "Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders." | 5.22 | Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. ( Abdelgalil, MS; Ali, MM; Benmelouka, AY; Brimo Alsaman, MZ; Elgendy, AMN; Elnaiem, W; Mogheeth, A; Yousof, SM, 2022) |
| "This 12-week study has an add-on, randomised, double-blind, placebo-controlled design of treatment with memantine, including an up-titration phase (forced flexible dose design, 5-15 mg/day), in patients aged 6-17 years and 9 months with obsessive-compulsive disorder or autism spectrum disorder." | 5.22 | Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial. ( Banaschewski, T; Buitelaar, JK; Dijkhuizen, RM; Dittmann, RW; Franke, B; Häge, A; Lythgoe, DJ; Mechler, K; Williams, SC, 2016) |
| "Memantine monotherapy was found to exert efficacy in several neuropsychiatric conditions, including autism spectrum disorder, binge eating disorder, and attention-deficit/hyperactivity disorder." | 4.98 | The use of memantine in neuropsychiatric disorders: An overview. ( Lu, S; Nasrallah, HA, 2018) |
| "To investigate the use of antipsychotics, benzodiazepine derivatives, and drugs recommended for dementia treatment (anticholinesterases [AChEIs] and memantine) among people with ID and dementia." | 3.85 | Use of antipsychotics, benzodiazepine derivatives, and dementia medication among older people with intellectual disability and/or autism spectrum disorder and dementia. ( Ahlström, G; Axmon, A; Kristensson, J; Midlöv, P, 2017) |
| "Memantine is an important addition to the psychopharmacological armamentarium." | 3.01 | Clinical Indications of Memantine in Psychiatry-Science or Art? ( Alayadhi, N; Aljuwaiser, M; Naguy, A; Ozidu, V; Rushdy, R; Shafik Zakhari, SA, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Soorya, LV | 1 |
| Fogg, L | 1 |
| Ocampo, E | 1 |
| Printen, M | 1 |
| Youngkin, S | 1 |
| Halpern, D | 1 |
| Kolevzon, A | 1 |
| Lee, S | 2 |
| Grodberg, D | 1 |
| Anagnostou, E | 1 |
| Elnaiem, W | 1 |
| Benmelouka, AY | 1 |
| Elgendy, AMN | 1 |
| Abdelgalil, MS | 1 |
| Brimo Alsaman, MZ | 1 |
| Mogheeth, A | 1 |
| Ali, MM | 1 |
| Yousof, SM | 1 |
| Brignell, A | 1 |
| Marraffa, C | 1 |
| Williams, K | 1 |
| May, T | 1 |
| Aljuwaiser, M | 1 |
| Alayadhi, N | 1 |
| Ozidu, V | 1 |
| Shafik Zakhari, SA | 1 |
| Rushdy, R | 1 |
| Naguy, A | 1 |
| Zohny, SM | 1 |
| Habib, MZ | 1 |
| Mohamad, MI | 1 |
| Elayat, WM | 1 |
| Elhossiny, RM | 1 |
| El-Salam, MFA | 1 |
| Hassan, GAM | 1 |
| Aboul-Fotouh, S | 1 |
| Mechler, K | 2 |
| Häge, A | 2 |
| Schweinfurth, N | 1 |
| Glennon, JC | 1 |
| Dijkhuizen, RM | 2 |
| Murphy, D | 1 |
| Durston, S | 1 |
| Williams, S | 1 |
| K Buitelaar, J | 1 |
| Banaschewski, T | 2 |
| Dittmann, RW | 2 |
| Tactics Consortium, T | 1 |
| Lu, S | 1 |
| Nasrallah, HA | 1 |
| Chung, C | 1 |
| Ha, S | 1 |
| Kang, H | 1 |
| Lee, J | 1 |
| Um, SM | 1 |
| Yan, H | 1 |
| Yoo, YE | 1 |
| Yoo, T | 1 |
| Jung, H | 1 |
| Lee, D | 1 |
| Lee, E | 1 |
| Kim, J | 1 |
| Kim, R | 1 |
| Kwon, Y | 1 |
| Kim, W | 1 |
| Kim, H | 2 |
| Duffney, L | 1 |
| Kim, D | 1 |
| Mah, W | 1 |
| Won, H | 1 |
| Mo, S | 1 |
| Kim, JY | 1 |
| Lim, CS | 1 |
| Kaang, BK | 1 |
| Boeckers, TM | 1 |
| Chung, Y | 1 |
| Jiang, YH | 1 |
| Kim, E | 1 |
| Hardan, AY | 1 |
| Hendren, RL | 1 |
| Aman, MG | 1 |
| Robb, A | 1 |
| Melmed, RD | 1 |
| Andersen, KA | 1 |
| Luchini, R | 1 |
| Rahman, R | 1 |
| Ali, S | 1 |
| Jia, XD | 1 |
| Mallick, M | 1 |
| Lateiner, JE | 1 |
| Palmer, RH | 1 |
| Graham, SM | 1 |
| Buitelaar, JK | 1 |
| Franke, B | 1 |
| Lythgoe, DJ | 1 |
| Williams, SC | 1 |
| Joshi, G | 1 |
| Wozniak, J | 1 |
| Faraone, SV | 1 |
| Fried, R | 1 |
| Chan, J | 1 |
| Furtak, S | 1 |
| Grimsley, E | 1 |
| Conroy, K | 1 |
| Kilcullen, JR | 1 |
| Woodworth, KY | 1 |
| Biederman, J | 1 |
| Axmon, A | 1 |
| Kristensson, J | 1 |
| Ahlström, G | 1 |
| Midlöv, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism Targeting Memory and Motor Planning[NCT01372449] | Phase 2 | 23 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism[NCT00872898] | Phase 2 | 124 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Memantine in Adult Autism Spectrum Disorder[NCT01078844] | 4 participants (Actual) | Interventional | 2010-02-28 | Terminated (stopped due to Sponsor withdrew funds) | |||
| Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions: A Randomized-controlled Trial[NCT03553875] | Phase 3 | 100 participants (Anticipated) | Interventional | 2018-11-13 | Recruiting | ||
| Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder[NCT01972074] | Phase 3 | 84 participants (Actual) | Interventional | 2015-02-17 | Completed | ||
| An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)[NCT01592773] | Phase 2 | 747 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Terminated because primary efficacy parameter failed to demonstrate statistically significant difference between memantine and placebo in controlled trials) | ||
| Development Of Cortical Metrics Assessment Outcome Measures in Response to Memantine Treatment in Autism Spectrum Disorders[NCT02353130] | 0 participants (Actual) | Observational | 2015-07-31 | Withdrawn (stopped due to Protocol did not continue once Investigator relocated to another institution) | |||
| A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With M[NCT01592747] | Phase 2 | 479 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Children's Communication Checklist-2 (CCC-2) Coherence Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).~The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties children may have (across 10 different subscales, consisting of 7 items each) that affect communication (items 1-50), as well as strengths that children may demonstrate when communicating with others (items 51-70)." (NCT00872898)
Timeframe: From Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.2 |
| Memantine | -1.2 |
"The Children's Communication Checklist-2 (CCC-2) Context Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).~The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties children may have (across 10 different subscales, consisting of 7 items each) that affect communication (items 1-50), as well as strengths that children may demonstrate when communicating with others (items 51-70)." (NCT00872898)
Timeframe: From Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.5 |
| Memantine | -0.2 |
"The Children's Communication Checklist-2 (CCC-2) Initiation Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).~The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties children may have (across 10 different subscales, consisting of 7 items each) that affect communication (items 1-50), as well as strengths that children may demonstrate when communicating with others (items 51-70)." (NCT00872898)
Timeframe: From Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.8 |
| Memantine | -0.9 |
"The Children's Communication Checklist-2 (CCC-2) Interests Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).~The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties children may have (across 10 different subscales, consisting of 7 items each) that affect communication (items 1-50), as well as strengths that children may demonstrate when communicating with others (items 51-70)." (NCT00872898)
Timeframe: From Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.5 |
| Memantine | -0.5 |
"The Children's Communication Checklist-2 (CCC-2) Nonverbal Communication Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).~The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties children may have (across 10 different subscales, consisting of 7 items each) that affect communication (items 1-50), as well as strengths that children may demonstrate when communicating with others (items 51-70)." (NCT00872898)
Timeframe: From Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.7 |
| Memantine | -0.9 |
"The Children's Communication Checklist-2 (CCC-2) Scripted Language Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).~The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties children may have (across 10 different subscales, consisting of 7 items each) that affect communication (items 1-50), as well as strengths that children may demonstrate when communicating with others (items 51-70)." (NCT00872898)
Timeframe: From Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.0 |
| Memantine | -0.5 |
"The Children's Communication Checklist-2 (CCC-2) Semantics Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).~The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties children may have (across 10 different subscales, consisting of 7 items each) that affect communication (items 1-50), as well as strengths that children may demonstrate when communicating with others (items 51-70)." (NCT00872898)
Timeframe: From Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.2 |
| Memantine | -0.5 |
"The Children's Communication Checklist-2 (CCC-2) Social Relations Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).~The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties children may have (across 10 different subscales, consisting of 7 items each) that affect communication (items 1-50), as well as strengths that children may demonstrate when communicating with others (items 51-70)." (NCT00872898)
Timeframe: From Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.0 |
| Memantine | -0.8 |
"The Children's Communication Checklist-2 (CCC-2) Speech Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).~The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties children may have (across 10 different subscales, consisting of 7 items each) that affect communication (items 1-50), as well as strengths that children may demonstrate when communicating with others (items 51-70)." (NCT00872898)
Timeframe: From Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.4 |
| Memantine | -0.7 |
"The Children's Communication Checklist-2 (CCC-2) Syntax Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe).~The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties children may have (across 10 different subscales, consisting of 7 items each) that affect communication (items 1-50), as well as strengths that children may demonstrate when communicating with others (items 51-70)." (NCT00872898)
Timeframe: From Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.1 |
| Memantine | -1.2 |
"The Social Responsiveness Scale (SRS) is a 65-item informant-rated assessment, ranging from 0 (no impairment) to 195 (severe social impairment).~Each item is associated with 1 of 5 subscales (social awareness, social cognition, social communication, social motivation and autistic mannerisms). Each item is rated on a 4-point scale from 1 (not true) to 4 (almost always true). The scores are then transposed to a scale from 0 to 3 and scores are summed within each of the 5 subscales. A higher score indicates greater severity of social impairment." (NCT00872898)
Timeframe: From Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -9.5 |
| Memantine | -9.6 |
"The Core Autism Treatment Scale-Improvement (CATS-I) Communication Subscale is based on rating 5 items from 1 (very much improved) to 7 (very much worse) with a total score ranging from 5 (improved) to 35 (worsened).~The Core Autism Treatment Scale-Improvement (CATS-I) is designed to utilize a comparison between pretreatment ratings of Core Autism Treatment Scale-Severity (CATS-S) and ratings of improvement after start of therapy (CATS-I). Both parts of the CATS contain 14 items testing for social interaction (items 1-9) and communication (items 10-14). Each of these items is rated from 1 (indicating most benign) to 7 (indicating most severe)." (NCT00872898)
Timeframe: At Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 18.0 |
| Memantine | 17.2 |
"The Core Autism Treatment Scale-Improvement (CATS-I) Social Interaction Subscale is based on rating 9 items from 1 (very much improved) to 7 (very much worse) with a total score ranging from 9 (improved) to 63 (worsened).~The Core Autism Treatment Scale-Improvement (CATS-I) is designed to utilize a comparison between pretreatment ratings of Core Autism Treatment Scale-Severity (CATS-S) and ratings of improvement after start of therapy (CATS-I). Both parts of the CATS contain 14 items testing for social interaction (items 1-9) and communication (items 10-14). Each of these items is rated from 1 (indicating most benign) to 7 (indicating most severe)." (NCT00872898)
Timeframe: At Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 32.4 |
| Memantine | 31.1 |
"The Core Autism Treatment Scale-Improvement (CATS-I) is based on rating 14 items from 1 (very much improved) to 7 (very much worse) with a total score ranging from 14 (improved) to 98 (worsened).~The Core Autism Treatment Scale-Improvement (CATS-I) is designed to utilize a comparison between pretreatment ratings of Core Autism Treatment Scale-Severity (CATS-S) and ratings of improvement after start of therapy (CATS-I). Both parts of the CATS contain 14 items testing for social interaction (items 1-9) and communication (items 10-14). Each of these items is rated from 1 (indicating most benign) to 7 (indicating most severe)." (NCT00872898)
Timeframe: At Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 50.4 |
| Memantine | 48.3 |
Area under the plasma concentration vs. time curve (AUC) for memantine, as measured in units of nanogram x hours per milliliter. (NCT00872898)
Timeframe: Baseline to 144 hours. Measurements were taken 0 (predose), 4, 8, 24, 30, 48, 96 and 144 hours post-dose
| Intervention | ng•h/mL (Mean) |
|---|---|
| Memantine | 682.53 |
Treatment responders are defined as having a 25% reduction, from baseline to endpoint, in Social Responsiveness Scale, Second Edition: School-Age, Parent Report (SRS-2) total raw score and an Autism Spectrum Disorder Clinical Global Impression-Improvement (ASD CGI-I) score ≤2. The Social Responsiveness Scale, Second Edition (SRS-2) is a 65-item rating scale completed by the parents/guardians of children ages 4-18. It is used to measure the severity of autism spectrum disorder symptoms. Each item is rated on a 4-point Likert scale, ranging from 1=Not True to 4=Almost Always True. Higher scores indicate a higher severity of autism spectrum disorder symptoms. The Autism Spectrum Disorder Clinical Global Impression-Improvement subscale (ASD CGI-I) is a clinician-rated measure of the improvement of autism spectrum disorder symptoms. The subscale is rated on a 7-point Likert scale, ranging from 1=Very Much Improved to 7=Very Much Worse. Higher scores indicate less symptom improvement. (NCT01972074)
Timeframe: 12 Weeks (from Baseline [Week 0] to Endpoint [Week 12])
| Intervention | Participants (Count of Participants) |
|---|---|
| Memantine | 9 |
| Placebo | 4 |
Number of patients who experienced 1 or more Treatment Emergent Adverse Event (NCT01592773)
Timeframe: Visit 1 (Week 0) up to 30 days after Visit 8 (up to Week 48) or Final Visit
| Intervention | participants (Number) |
|---|---|
| Memantine | 424 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Coherence Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). (NCT01592747)
Timeframe: Baseline (Visit 1) to week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.7 |
| Memantine Reduced Dose | 1.0 |
| Memantine Full-Dose | 1.0 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Context Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). (NCT01592747)
Timeframe: Baseline (Visit 1) to week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.9 |
| Memantine Reduced Dose | 0.8 |
| Memantine Full-Dose | 0.8 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Initiation Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). (NCT01592747)
Timeframe: Baseline (Visit 1) to week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.4 |
| Memantine Reduced Dose | 1.6 |
| Memantine Full-Dose | 1.2 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Interests Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). (NCT01592747)
Timeframe: Baseline (Visit 1) to week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.9 |
| Memantine Reduced Dose | 1.3 |
| Memantine Full-Dose | 1.2 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Nonverbal communication Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). (NCT01592747)
Timeframe: Baseline (Visit 1) to week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Memantine Reduced Dose | 1.5 |
| Memantine Full-Dose | 1.8 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Scripted language Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). (NCT01592747)
Timeframe: Baseline (Visit 1) to week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.8 |
| Memantine Reduced Dose | 1.1 |
| Memantine Full-Dose | 0.9 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Semantics Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). (NCT01592747)
Timeframe: Baseline (Visit 1) to week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Memantine Reduced Dose | 0.7 |
| Memantine Full-Dose | 0.3 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Social Relations Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). (NCT01592747)
Timeframe: Baseline (Visit 1) to week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.5 |
| Memantine Reduced Dose | 1.8 |
| Memantine Full-Dose | 1.8 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Speech Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). (NCT01592747)
Timeframe: Baseline (Visit 1) to week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.1 |
| Memantine Reduced Dose | 0.1 |
| Memantine Full-Dose | 0.2 |
The Children's Communication Checklist-2 (CCC-2) is a validated, norm-referenced, informant-rated scale that evaluates difficulties (items 1-50) and strengths (items 51-70) in communication. There are 10 sub-scales consisting of 7 items each. The Children's Communication Checklist-2 (CCC-2) Syntax Subscale consists of 7 items rated from 0 (less than once a week or never) to 3 (several times [more than twice] a day or always), with a total raw score of 0 (mildest) to 21 (most severe). (NCT01592747)
Timeframe: Baseline (Visit 1) to week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.0 |
| Memantine Reduced Dose | 0.3 |
| Memantine Full-Dose | 0.1 |
Loss of Therapeutic response is defined as a worsening (increase) of at least 10 points in Social Responsiveness Scale (SRS) total raw score relative to the Visit 1 (randomization) score. The Social Responsiveness Scale (SRS) is a 65-item informant-rated assessment with total raw score ranging from 0 (no impairment) to 195 (severe social impairment). Each item is associated with 1 of 5 subscales (social awareness, social cognition, social communication, social motivation and autistic mannerisms). Each item is rated on a 4-point scale from 1 (not true) to 4 (almost always true). The scores are then transposed to a scale from 0 to 3 and scores are summed within each of the 5 subscales. A higher score indicates greater severity of social impairment. (NCT01592747)
Timeframe: Baseline (Visit 1) to week 12
| Intervention | Percentage of patients with LTR (Number) |
|---|---|
| Placebo | 69.0 |
| Memantine Reduced Dose | 67.5 |
| Memantine Full-Dose | 66.7 |
Time to the first visit when a patient shows LTR following randomization to memantine or placebo. (NCT01592747)
Timeframe: Baseline to week 12
| Intervention | Days (Median) |
|---|---|
| Placebo | 29 |
| Memantine Reduced Dose | 33 |
| Memantine Full-Dose | 30 |
5 reviews available for memantine and Autism Spectrum Disorder
| Article | Year |
|---|---|
Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis.
Topics: Anxiety Disorders; Autism Spectrum Disorder; Child; Excitatory Amino Acid Antagonists; Humans; Meman | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Memantine for autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Female; Humans; Male; Memantine; Odds Ratio; Out | 2022 |
Clinical Indications of Memantine in Psychiatry-Science or Art?
Topics: Alzheimer Disease; Autism Spectrum Disorder; Humans; Memantine; Off-Label Use; Psychiatry | 2023 |
Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature.
Topics: Acetylcysteine; Adolescent; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; | 2018 |
The use of memantine in neuropsychiatric disorders: An overview.
Topics: Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Binge-Eating Disorder; Drug | 2018 |
4 trials available for memantine and Autism Spectrum Disorder
| Article | Year |
|---|---|
Neurocognitive Outcomes from Memantine: A Pilot, Double-Blind, Placebo-Controlled Trial in Children with Autism Spectrum Disorder.
Topics: Autism Spectrum Disorder; Behavior; Child; Cognition; Double-Blind Method; Excitatory Amino Acid Ant | 2021 |
Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies.
Topics: Autism Spectrum Disorder; Child; Delayed-Action Preparations; Double-Blind Method; Early Termination | 2019 |
Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
Topics: Adolescent; Adolescent Behavior; Autism Spectrum Disorder; Brain; Child; Child Behavior; Clinical Pr | 2016 |
A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Excitatory Amino Acid Antagonists; Female; Humans; Male | 2016 |
3 other studies available for memantine and Autism Spectrum Disorder
| Article | Year |
|---|---|
Memantine/Aripiprazole Combination Alleviates Cognitive Dysfunction in Valproic Acid Rat Model of Autism: Hippocampal CREB/BDNF Signaling and Glutamate Homeostasis.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Autistic Disorder; Brain-Derived Neurotrophic Facto | 2023 |
Early Correction of N-Methyl-D-Aspartate Receptor Function Improves Autistic-like Social Behaviors in Adult Shank2
Topics: Age Factors; Animals; Autism Spectrum Disorder; Behavior, Animal; Disease Models, Animal; Excitatory | 2019 |
Use of antipsychotics, benzodiazepine derivatives, and dementia medication among older people with intellectual disability and/or autism spectrum disorder and dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Autism Spectrum Disorder; Benzodiazepines; Cholineste | 2017 |